The 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver was attended by investigators from RePORT-Brazil, including presentations on recent findings and articles. Poster Presentations:Dr. Gustavo Amorim, PhD - "Estimating Optimal Anti-TB Drug Concentrations in a Prospective, Observational Cohort in Brazil"Dr. Felipe Ridolfi, PhD, MD - “Pharmacogenetic Associations With HIV-1 Virologic Suppression Among Patients with TB/HIV in Brazil”

A recently publication in the journal Clinical Infectious Diseases is catching attention. The Xpert® MTB/RIF cycle threshold value predicts M. tuberculosis transmission to close contacts in a Brazilian prospective multicenter cohort  was published by the RePORT-Brazil consortium, with authorship being led by the team at the Fundação de Medicina Tropical in Manaus, Amazonas, Brazil.  

CDC’s Tuberculosis Trials Consortium (TBTC) has recently launched the CRUSH-TB trial, which aims to identify new combinations of drugs to shorten treatment of active TB disease. Kelly Dooley, MD, PhD, MPH, Director, Division of Infectious Diseases, is a Protocol Chair for this new study. Read more from CDC’s TB Notes newsletter:

The Tennessee Center for AIDS Research (TN-CFAR) has issued a new funding announcement for their Developmental Core Awards. You can find more information here